Lewy body dementia (LBD) is a dementia from abnormal Lewy protein deposits, diagnosed by progressive thinking decline plus distinctive clinical features. Alzheimer's is diagnosed more often from early progressive memory loss plus amyloid and tau tests, rather than movement and sleep features. Both evaluations use history, neurologic examination, cognitive testing, routine labs, and MRI or CT to exclude mimics. Accurate separation guides referrals, follow-up timing, and medication safety.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which early symptoms point toward each condition?
- How do doctors diagnose Lewy body dementia?
- Why does Alzheimer's testing focus on biology?
- Which tests best separate LBD from Alzheimer's?
- Why does uncertainty remain common?
Which early symptoms point toward each condition?
The Mayo Clinic News Network explains that LBD centers on fluctuating attention and alertness Mayo Clinic Q and A on Lewy body dementia and Alzheimer's. Recurrent well-formed visual hallucinations, slowed movement and stiffness, and acting out dreams also point toward LBD.
Alzheimer's typically begins with trouble forming new memories and recalling recent events. The National Institute on Aging notes LBD mainly affects adults over 50 to 65 and is often first mistaken for Alzheimer's or psychiatric illness. Clinicians therefore track timing, dominant symptoms, and Parkinson-like signs before ordering special tests.
How do doctors diagnose Lewy body dementia?
No blood test or routine brain scan proves LBD during life. The National Institute of Neurological Disorders and Stroke states only postmortem brain autopsy confirms it with certainty. Doctors therefore diagnose from symptom pattern plus tests that exclude other causes. Under Dementia with Lewy Bodies Consortium criteria, presented by NW GWEC and Leverenz, two core features mean probable DLB.
One core feature plus an indicative biomarker also means probable DLB. One core feature alone, or dementia with only a suggestive feature, means possible DLB. Indicative biomarkers include REM sleep without muscle atonia on polysomnography and abnormal cardiac MIBG uptake. Severe sensitivity to typical antipsychotics adds supportive weight and is uncommon as a central Alzheimer's clue. The Cleveland Alzheimer's Disease Research Center lists these markers as key LBD indicators.
Why does Alzheimer's testing focus on biology?
The Alzheimer's Association reports growing use of biology-based tests for Alzheimer's pathology in life Alzheimer's Association guide to earlier diagnosis. Amyloid and tau PET scans visualize plaques and tangles. Cerebrospinal fluid amyloid and tau ratios and blood phosphorylated-tau 217 assays add laboratory confirmation.
LBD care does not have an equivalent single confirming blood or PET test. Both conditions still start with history, neurologic examination, cognitive testing, routine labs, and MRI or CT. Those steps look for another explanation before assigning dementia type.
Which tests best separate LBD from Alzheimer's?
Practical Neurology reports reduced dopamine-transporter uptake on DaTscan SPECT or PET favors LBD over Alzheimer's Practical Neurology guide to dementia with Lewy bodies. Uptake is often abnormal in LBD and Parkinson's disease but typically normal in Alzheimer's. For DLB versus Alzheimer's, sensitivity is about 78% and specificity about 90%.
Clinicians often contrast results this way: The National Institute on Aging notes accurate distinction changes care National Institute on Aging guide to Lewy body dementia. LBD often needs neurologist referral, repeated visits, and avoidance of typical antipsychotics. Families can ask what each test rules in, what it rules out, and how it changes treatment.
- DaTscan abnormal supports LBD, while a normal scan favors Alzheimer's
- Dream enactment with loss of normal muscle limpness in REM sleep supports LBD
- Markedly reduced cardiac MIBG uptake supports LBD
- Positive amyloid or tau PET, spinal fluid, or p-tau 217 supports Alzheimer's
Why does uncertainty remain common?
About half of LBD cases show Alzheimer's changes, while about 30% of Alzheimer's cases show Lewy pathology. Mixed pathology can blur memory, hallucination, and movement patterns. A single visit may therefore capture only part of the course.
Early change may also look like psychiatric illness, especially when hallucinations or fluctuations dominate. Doctors may schedule more than one visit to watch alertness, sleep behavior, and drug response. Bring a sleep partner's account, a complete drug list, and dated examples of confusion and clear periods.
